Using TCR-CAR dual signaling for precise cancer targeting.

IF 13.1 1区医学 Q1 IMMUNOLOGY

Trends in Immunology Pub Date : 2025-05-13 DOI:10.1016/j.it.2025.04.007

Mohammad Shahbazy, Isabelle Rose Leo, Pouya Faridi, Etienne Caron

引用次数: 0

Abstract

Recently, Kondo et al. engineered the coexpression of a T cell receptor (TCR) and a chimeric antigen receptor (CAR) and developed an antagonism-enforced braking system where TCR signals both enhance and inhibit CAR activation. This work may enable rational design of CAR-T agents that limit toxicity to healthy tissue.

查看原文本刊更多论文

利用TCR-CAR双信号精确靶向癌症。

最近，Kondo等人设计了T细胞受体（TCR）和嵌合抗原受体（CAR）的共表达，并开发了一种拮抗强制制动系统，其中TCR信号可以增强和抑制CAR的激活。这项工作可能使CAR-T药物的合理设计，以限制对健康组织的毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in Immunology 医学-免疫学

CiteScore

25.10

自引率

0.60%

发文量

130

审稿时长

6-12 weeks

期刊介绍： Trends in Immunology serves as a vital platform for tracking advancements across various areas of immunology, offering concise reviews and hypothesis-driven viewpoints in each issue. With additional sections providing comprehensive coverage, the journal offers a holistic view of immunology. This broad perspective makes it an invaluable resource for researchers, educators, and students, facilitating the connection between basic and clinical immunology. Recognized as one of the top monthly review journals in its field, Trends in Immunology is highly regarded by the scientific community.